Though ischemic outcomes numerically favored the Amulet, confirmation in future studies is needed, experts say.

The drug was approved last year for patients with hypertension currently not controlled on other BP-lowering agents.

David Ferreira talks to C. Michael Gibson about the latest data showing patients don't need to fast ahead of cardiac ...

The transition from adolescence can bring decreased physical activity, a worse diet, and little focus on overall CV health.

For every 100,000 runners who complete the full 42.2 km distance, there will be one cardiac arrest, new data show.

Whether newer pacing techniques can mitigate death, LV decline, and HF symptoms in TAVI patients remains to be seen.

The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

AI outperformed clinicians and almost matched hs-TnT testing, but one expert questioned if this is where it’s needed most.

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...